Pierre Massion to direct Vanderbilt-Ingram’s early detection initiative

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

PIERRE MASSION will direct the Vanderbilt-Ingram Cancer Center’s Cancer Early Detection and Prevention Initiative. Massion is the Cornelius Vanderbilt Professor of Medicine, an Ingram Professor of Cancer Research and co-leader of the VICC Cancer Health Outcomes and Control Research Program.

“The prevention of cancer and the development of more effective strategies to detect cancer precursors and early-stage cancers, when treatment may be most effective, remain top goals of Vanderbilt University Medical Center and we are pleased that Pierre has agreed to lead this new initiative,” said Jennifer Pietenpol, executive vice president for research at VUMC and director of the cancer center. “As we develop a better understanding of environment and lifestyle factors, and common genetic variants that are associated with higher or lower risk of certain cancers, we may be able to use that knowledge to identify individuals who may benefit from early detection and prevention strategies.”

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login